These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23621771)

  • 21. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.
    Klimek VM; Dolezal EK; Tees MT; Devlin SM; Stein K; Romero A; Nimer SD
    Leuk Res; 2012 Sep; 36(9):1093-7. PubMed ID: 22608310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy.
    Breccia M; Molica M; Zacheo I; Alimena G
    Expert Opin Pharmacother; 2014 Aug; 15(11):1621-30. PubMed ID: 24989987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decitabine in the treatment of myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.
    Tenti E; Papayannidis C; Marconi G; Parisi S; Simonetti G; Paolini S; Sartor C; Ottaviani E; Testoni N; Martinelli G
    Expert Opin Pharmacother; 2016 Dec; 17(18):2479-2486. PubMed ID: 27829292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience.
    Papoutselis M; Douvali E; Papadopoulos V; Spanoudakis E; Margaritis D; Tsatalas C; Kotsianidis I
    Leuk Res; 2014 Feb; 38(2):161-5. PubMed ID: 24239174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azacitidine: in myelodysplastic syndromes.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(13):1781-9; discussion 1790-1. PubMed ID: 16114977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azacitidine. Poor-prognosis myelodysplasia: promising, but more data needed.
    Prescrire Int; 2011 Feb; 20(113):40. PubMed ID: 21488589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
    Takahashi Y; Kimura S; Okano M
    Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
    [No Abstract]   [Full Text] [Related]  

  • 30. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
    Abáigar M; Ramos F; Benito R; Díez-Campelo M; Sánchez-del-Real J; Hermosín L; Rodríguez JN; Aguilar C; Recio I; Alonso JM; de las Heras N; Megido M; Fuertes M; del Cañizo MC; Hernández-Rivas JM
    Ann Hematol; 2013 Nov; 92(11):1543-52. PubMed ID: 23740492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azacitidine adverse effects in patients with myelodysplastic syndromes.
    San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of azacitidine in myelodysplastic syndromes.
    Vigil CE; Martin-Santos T; Garcia-Manero G
    Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
    Lamprianidou E; Zoulia E; Bernard E; Kordella C; Papoutselis M; Bezirgiannidou Z; Vrachiolias G; Papaemmanuil E; Kotsianidis I
    Leuk Lymphoma; 2019 Dec; 60(13):3277-3281. PubMed ID: 31185765
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of azacitidine in the treatment of myelodysplastic syndromes.
    Abdulhaq H; Rossetti JM
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1967-75. PubMed ID: 18042004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
    Steensma DP; Stone RM
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
    Maslak P; Chanel S; Camacho LH; Soignet S; Pandolfi PP; Guernah I; Warrell R; Nimer S
    Leukemia; 2006 Feb; 20(2):212-7. PubMed ID: 16357841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
    Adès L; Itzykson R; Fenaux P
    Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing hypomethylating agents in myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.